CagriSema is a fixed combination of two peptides cagrilintide, an amylin analogue, plus semaglutide, a GLP-1 receptor agonist
Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo
Liver Int 2011, 31 (9), 13151324
Mitochondrial etiology of neuropsychiatric disorders
Common research applications include single-receptor pharmacology (semaglutide and liraglutide as GLP-1 reference agonists), dual-receptor comparison studies (tirzepatide for GIP/GLP-1, mazdutide and survodutide for GLP-1/glucagon), triple-receptor research (retatrutide), and multi-pathway combinations using amylin agonists alongside incretin agonists (cagri-sema, retatrutide+cagrilintide)
The supplement features a convenient 1-capsule daily dosage with 500 mg of L-Carnitine per serving